Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction

American Heart Journal

Volumn 131, Issue 3, 1996, Pages 421-433

  Becker, Richard C ^a   Cannon, Christopher P ^b   Tracy, Russell P ^c   Thompson, Bruce ^d   Bovill, Edwin G ^c   Desvigne Nickens, Patrice ^d   Randall, A M Y ^d   Knatternud, Genell ^d   Braunwald, Eugene ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

EID: 0029997235     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90519-0     Document Type: Article

References (66)

1. Vital Health Statistics. Detailed diagnosis and procedures for patients discharged from short stay hospitals. Hyattsville, Md.: US Department of Health and Human Services, Public Health Service, National Center for Health Statistics, 1987.
2. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evaluation of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986;7:474-8.
3. Williams AE, Freeman MR, Chisolm RJ, Patt NL, Armstrong PW. Angiographic morphology in unstable angina pectoris. Am J Cardiol 62:1024-7.
4. Vetrovec G, Leinback R, Gold HK, Cowley MJ. Intracoronary thrombolysis in syndromes of unstable ischemia: angiographic and clinical results. AM HEART J 1982;104(2):946-52.
5. Mandelkorn J, Wolf N, Singh S, Schechter JA, Kersh RI, Rodgers DM, Workman MB, Bentivoglio LG, LaPorte SM, Meister SG. Intracoronary thrombus in nontransmural myocardial infarction and in unstable angina pectoris. Am J Cardiol 1983;52:1-6.
6. Ridolfi RL, Hutchins GM. The relationship between coronary artery lesions and myocardial infarcts: ulceration of the atherosclerotic plaques precipitating coronary thrombosis. AM HEART J 1977;93:468.
7. Davies MJ, Thomas MB. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137-40.
8. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading in infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolizations culminating in total vasacular occlusion. Circulation 1985;71:699-708.
9. Horie T, Sekiguchi M, Kirosawa K. Coronary thrombosis in pathogenesis of acute myocardial infarction: histophysiological study of coronary arteries in 108 necropsied cases using serial section. Br Heart J 1978; 40:153-61.
10. Sherman CT, Litvack F, Gundfest T, Lee M, Hickey A, Chaux A, Kass R, Blance C, Matoff J, Morgenstern L, Ganz W, Swan HJC, Forrester J. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315:913-9.
11. Uchida Y, Fujimori Y, Hirose J, Oshima T. Percutaneous coronary angioscopy. Jpn Heart J 1992;33:271-94.
12. Mizuno K, Satumora K, Miyamoto A, Arakawa E, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose J. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287-91.
13. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, DeGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
14. Theroux P, Waters D, Qui S, McCans J, deGuise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88(part 1):2045-8.
15. Basu D, Galluis A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7.
16. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315: 1109-14.
17. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-7.
18. Hsia J, Hamilton WP, Kleiman N. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433- 7.
19. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-7.
20. deBono DP, Simoons ML, Tijssen, for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-8.
21. TIMI III B Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Results of the TIMI III B Trial. Circulation 1994;89:1545-56.
22. Cruickshank MK, Levine MN, Hirsch J, Roberts R, and Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-7.
23. Terien An Lie M. Evaluation of an aminolytic heparin assay method. Increased sensitivity by adding purified antithrombin III. Thromb Res 1977;20L:399-410.
24. Turpie AGG, Robinson JB, Doyle DJ Mulji AM, Mishkel G, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M. Comparison of high dose with low dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320:353-7.
25. Tracy RP, Kleiman N, Thompson BW, for the Thrombolysis in Myocardial Infarction Study Group. Relationships of coagulation parameters to patency at 18-48 hours in the Thrombolysis in Myocardial Infarction trial [Abstract]. Clin Res 1991;39:239A.
26. Arnout J, Simmons M, DeBono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 1992;20:313-9.
27. Hsia J, Kleiman N, Aquire F, Chaitman B, Roberts R, Ross AM, for the HART Investigators. Heparin-induced prolongation of partial thromboplastin time and thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 1992;20:31-5.
28. Nichol ES, Phillips WC, Casten GG. Virtue of prompt anticoagulant therapy in impending myocardial infarction: experiences with 318 patients during a 10 year period. Ann Intern Med 1959;50:1158-73.
29. Beamish RE, Storrie VM. Impending myocardial infarction: recognition and management. Circulation 1960;21:1107-15.
30. Wood P. Acute and subacute coronary insufficiency. Br Heart J 1961; 1:1179-82.
31. Vakil RJ. Preinfarction syndrome-management and follow-up. Am J Cardiol 1964;14:55-63.
32. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;1:1225-8.
33. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
34. Neri Serneri GG, Gensini GP, Poggesi L. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina. Lancet 1990;335:615-8.
35. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A Trial. Circulation 1994; 90:1624-30.
36. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lia Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-7.
37. Heras M, Chesebro JH, Penny WJ, Baily KR, Lam JYT, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78:654-60.
38. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin form inactivation by heparin-anti-thrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989;86:3619-23.
39. Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-anti-thrombin complex. J Clin Invest 1983;71:1383-91.
40. Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to sub-endothelial extracellular matrix. J Clin Invest 1989;84:1096-104.
41. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-anti-thrombin III but is susceptible to inactivation by anti-thrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
42. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation 1884;89:1157-66.
43. Fuchs J, McCabe CH, Antman EM, Borzak S, Palisaitis D, Herson S. Hirulog in the treatment of unstable angina: results of the TIMI 7 Trial. J Am Coll Cardiol 1994;56A:1A-484A.
44. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:622-9.
45. Sharma GV, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 1993;72:1357-60.
46. Lidón RM, Théroux P, Lespérance J, Adelman B, Bonan R, Duval D, Lévesque J. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-72.
47. Lidón RM, Théroux P, Juneau M, Adelman B, Maraganore J. Initial experience with direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation 1993; 88(part 1):1495-501.
48. Tracy RP, Bovill EG, Ault KA, Becker RC, Mann KG. The measurement of platelet activation in clinical studies using frozen samples [Abstract]. Blood 1991;78(suppl 1):492a.
49. Becker RC, Tracy RP, Bovill EG, Mann KG, Ault K, for the TIMI Thrombosis and Anticoagulation Study Group. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. Cor Art Dis 1994;5:339-45.
50. Becker RC, Tracy RP, Bovill EG, Mann KG, Ault K, for the TIMI Thrombosis and Anticoagulation Study Group. Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q wave myocardial infarction. J Thromb Thrombolysis 1994;1:95-100.
51. Becker RC, Bovill EG, Corrao JM, Ball SP, Ault K, Mann KG, Tracy RP. Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q wave myocardial infarction. J Thromb Thrombolysis 1995;2:57-64.
52. Lewis DH, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;7:396-403.
53. Cairnes JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey GJ, Transer PH. Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med 1985;313:1369-75.
54. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320-31.
55. The TIMI IIIA Investigators. Early effects of tissue type plasminogen activator added to conventional therapy on the culprit lesion in patients presenting with ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial Ischemia (TIMI IIA) Trial. Circulation 1993;87:38-52.
56. White HD, Charbonnier B, van de Werf F. An aspirin-controlled study of MK-852 in patients with unstable angina. Circulation 1993; 88:II-201.
57. Theroux P, White H, David H. A heparin-controlled study of MK-383 in unstable angina. Circulation 1994;90:I-231.
58. Simoons ML, deBoer Jan M, Van deBrand MJBM, Can Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, Van der Weiken LR, deBono D, Rutsch W, et al. For the European Cooperative Study Group. Randomized trial of GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
59. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327:141-5.
60. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Dronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q wave infarction in non-prior aspirin users: primary end-points analysis from the ATACS Trial. Circulation 1994;89:81-8.
61. Yamagishi M, Miyatake K, Tamai J, Nakatani S, Koyama J, Nissen SE. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. J Am Coll Cardiol 1994;23:352-7.
62. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 1992;85:1706-72.
63. Lee C, Mann KG. The activation/inactivation of human factor V by plasmin. Blood 1989;73:185-90.
64. Penny WF, Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood 1992;79:91-8.
65. Lidon RM, Theroux P, Juneau M, DeGuise P, Lam JYT, Pelletier G, Waters D. The partial thromboplastin time during episodes of recurrent ischemic pain in unstable angina patients treated with heparin [Abstract]. Circulation 1992;86:I-857.
66. Becker R, Tracy R, Bovill E, Thompson B, Randall A, Cannon C, Braunwald E. Should aPTT assays be standardized in multicenter clinical trials designed to investigate the benefits of heparin? [Abstract] J Am Coll Cardiol 1994;(suppl A):57A.